Professor of Urology, Radiology, and Biomedical Engineering
Director, Division of Urologic Oncology NYU Grossman School of Medicine and Tandon School of Engineering, New York, USA
Speech Titles: 1) State of the Art Prostate MRI: What have we proven and where can we go further?
2) Imaging Cases
Samir S. Taneja, MD is the James M. and Janet Riha Neissa Professor of Urologic Oncology; Professor of Urology, Radiology, and Biomedical Engineering; GU Program Leader in the Perlmutter Cancer Center; Director of the Division of Urologic Oncology, and Vice Chair in the Department of Urology at NYU Langone Health. He received his undergraduate and medical education at Northwestern University Medical School. He completed his surgical and urologic training at the University of California at Los Angeles and joined the NYU faculty in 1996. Dr. Taneja is nationally renowned as a leader in the treatment and research of urologic cancers. His clinical practice has focused upon prostate cancer diagnosis and treatment, including robotic-assisted radical prostatectomy and focal ablative therapies, as well as the surgical treatment of renal cancers.
His previous laboratory research has focused in androgen receptor transcriptional activation and the relationship of AR to prostate cancer growth, for which he has received funding through the National Institutes of Health, Department of Defense, and the Prostate Cancer Foundation. Over the past decade, his clinical research interest has been in prostate cancer diagnostics, with particular focus on the application of imaging in the detection, risk stratification, and surgical therapy of prostate cancer. He has pioneered the clinical application of pre-biopsy prostate MRI and techniques of MRI-targeted biopsy using MRI to ultrasound co-registration (fusion) techniques. Dr. Taneja is also widely recognized as one of the most experienced innovators in the emerging field of prostate cancer focal therapy, having led and completed both single and multi-center clinical trials at NYULH, and has utilized a wide spectrum of focal therapy energy sources in clinical practice. Dr. Taneja has previously served on the AUA/ABU Joint Examination Committee, the SUO Oncology Knowledge Assessment Test Committee, and is previous Secretary General and past-President of the Urologic Research Society. He is an oral examiner for the American Board of Urology, a member of the Society of Urologic Oncology Board of Directors as Membership Committee Chair, and is an elected member of the American Association of Genitourinary Surgeons. He has authored over 250 articles, 25 book chapters, and 5 textbooks and periodicals on urologic cancer and urologic surgery. He has an h-index of 59. He serves on the editorial board of several journals, is the Consulting Editor of the Urologic Clinics of North America, the previous Upper Tract Oncology and current Prostate Cancer Urology Surveys contributor for the Journal of Urology, and editor of the 3rd, 4th, and 5th, editions of Taneja’s Complications of Urologic Surgery: Prevention and Diagnosis, one of the most widely read textbooks in American urology.